Risk calculator
PREVENT reports ASCVD risk (not total CVD); postal-code social deprivation is not used, and when both HbA1c and UACR are entered the full model treats it as missing, as the AHA calculator does without a ZIP code. Framingham reports 10-year total CVD risk using the CCS points method, doubled for family history as in the CCS modified FRS.
Adults 30–79 · no clinical ASCVD
PREVENT + risk enhancers
PREVENT 10-yr ASCVD
—
PREVENT 30-yr ASCVD (ages 30–59)
—
Framingham 10-yr CVD (CCS modified)—
Lipid treatment algorithm
Suggested action — ACC/AHA
Enter the patient’s details and press Calculate. The matching boxes below will be highlighted.
0Skip the calculator — treat directlyClinical ASCVD → secondary prevention (not covered here)
APPLIESLDL-C ≥4.9 mmol/LMax-tolerated statin; assess for FH. Don’t use risk calculators. Goal LDL-C <2.6 (<1.8 if HeFH).
APPLIESDiabetes, age 40–75Moderate statin 1. Consider high-intensity if multiple risk factors 2a.
APPLIESCKD stage 3–4, age 40–75eGFR 15–59: LDL-lowering therapy regardless of LDL-C.
APPLIESHIV on stable ART, 40–75Statin recommended 1 to prevent a first ASCVD event.
1Calculate — PREVENT 10-yr ASCVD riskFor LDL-C 1.8–4.8 mmol/L
LOW<3%
Lifestyle counseling 1
Age 30–59: check 30-yr risk.
Consider moderate statin 2a if:
• LDL-C 4.1–4.8, or
• 30-yr ASCVD risk ≥10%
• LDL-C 4.1–4.8, or
• 30-yr ASCVD risk ≥10%
BORDERLINE3–<5%
Discuss; check risk enhancers ↓ 2a
Enhancers present → consider moderate statin 2a, 30–49% LDL-C ↓
hsCRP ≥2 mg/L ×2 → consider high-intensity 2a
Goal LDL-C <2.6 · non-HDL <3.4
INTERMEDIATE5–<10%
After discussion: at least moderate statin 1, 30–49% ↓
Upper end of range → high-intensity 1, ≥50% ↓
Risk enhancers ↓ favor starting and higher intensity
Goal LDL-C <2.6 · non-HDL <3.4
HIGH≥10%
High-intensity statin 1, ≥50% LDL-C ↓
Not at goal on max statin → consider ezetimibe 2a
Goal LDL-C <1.8 · non-HDL <2.6
2Personalize — risk enhancersTick what applies · mainly for borderline & intermediate · 0 selected
1Statin-indicated conditions — statin, no FRS neededClinical ASCVD → secondary prevention (not covered here)
APPLIESLDL-C ≥5.0 mmol/Lor apoB ≥1.45 g/L or non-HDL-C ≥5.8 mmol/L — likely genetic dyslipidemia (e.g. FH).
APPLIESDiabetesAge ≥40; or age ≥30 with ≥15 years’ duration; or microvascular disease.
APPLIESCKD, age ≥50Not on dialysis: eGFR <60, or ACR ≥3.0 mg/mmol for ≥3 months.
Abdominal aortic aneurysm>3.0 cm, or previous aneurysm repair.
On maximally tolerated statin: if LDL-C ≥2.0 (non-HDL-C ≥2.6 or apoB ≥0.8) → add ezetimibe (bile acid sequestrant as alternative). For LDL-C ≥5.0 / FH: threshold LDL-C ≥2.5 or <50% reduction; PCSK9 inhibitor if still above.
2Calculate — Framingham 10-yr CVD riskNo statin-indicated condition · reassess every 5 yr at ages 40–75
LOW<10%
Health behaviour changes; statin generally not indicated.
FRS 5–9.9% with LDL-C ≥3.5, non-HDL-C ≥4.2 or apoB ≥1.05 → consider statin, especially with risk modifiers ↓.
INTERMEDIATE10–19.9%
Statin if LDL-C ≥3.5, non-HDL-C ≥4.2 or apoB ≥1.05.
Below these: consider statin in men ≥50 / women ≥60 with ≥1 risk factor ↓, or with risk modifiers ↓.
On statin: aim ≥50% LDL-C ↓; LDL-C ≥2.0 → consider ezetimibe
HIGH≥20%
Statin for all.
Health behaviour changes for all.
On statin: aim ≥50% LDL-C ↓; LDL-C ≥2.0 → add ezetimibe
3Additional risk factors & modifiersMainly for intermediate (and FRS 5–9.9%) · 0 present